Version 1.0 — Published August 2026
Quick Answer
Toxic shock syndrome (TSS) is a high-yield medicine and infectious-disease case on NEET PG — the CDC diagnostic criteria, superantigen mechanism, clindamycin plus vancomycin combination, and IVIG for streptococcal TSS appear reliably. A 22-year-old woman on day 4 of menses using a super-absorbent tampon with fever 40 degrees Celsius, diffuse sunburn-like erythroderma, hypotension 82/48, delirium, myalgia, vomiting-diarrhoea, and multi-organ dysfunction needs the following 10-step workflow:
- Recognise the pattern — fever plus rash plus hypotension plus multi-organ dysfunction plus mucous membrane findings equals TSS until proven otherwise
- Apply the CDC criteria — for menstrual staphylococcal TSS the fever-rash-hypotension-desquamation-3-organ-system-involvement checklist
- Remove the source — take out the tampon immediately, irrigate the vagina, look for and drain any soft-tissue focus
- First-hour sepsis bundle — 30 mL/kg crystalloid, blood cultures times two, lactate, empiric broad-spectrum antibiotics within 60 minutes
- Antibiotics — vancomycin plus clindamycin (Eagle effect, halts toxin production) plus piperacillin-tazobactam or meropenem; de-escalate after cultures
- Vasopressor — norepinephrine first-line for MAP over 65; add vasopressin then hydrocortisone for refractory shock
- IVIG 2 g/kg — recommended for streptococcal TSS and severe or refractory staphylococcal TSS as adjunct
- Organ support — mechanical ventilation for ARDS, renal replacement therapy for AKI, FFP and platelets for DIC, stress ulcer prophylaxis, VTE prophylaxis, nutrition
- Differential — rule out septic shock, meningococcaemia, leptospirosis, Kawasaki, scarlet fever, SJS/TEN, drug rash
- Prevention — tampon rotation every 4-8 hours, lowest absorbency, alternate with pads, no tampons after recurrent TSS, Staphylococcus decolonisation with mupirocin plus chlorhexidine
The case
A 22-year-old female medical student is brought to the emergency department of a tertiary hospital in Mumbai by her roommate with 3 days of high fever, worsening headache, generalised body ache, vomiting, and diarrhoea. She is currently on day 4 of her menstrual period and has been using super-absorbent tampons every 4-6 hours (she started using tampons 3 months ago for the convenience of clinical rotations; a rare choice in India but rising among urban young women).
The illness began 3 days ago with a sudden high-grade fever of 40 degrees Celsius with rigors, unresponsive to paracetamol 500 mg every 6 hours. Over the next 24 hours she developed severe generalised myalgia ("my whole body feels crushed"), throbbing headache, sore throat, and 4-5 episodes of watery non-bloody diarrhoea with 3 episodes of vomiting. Yesterday she noted a diffuse red rash resembling severe sunburn appearing on her trunk and spreading to her limbs. Today she has been progressively confused and drowsy, her roommate noted she was slurring her words and could not remember the day of the week. She has not passed urine for over 12 hours.
Menstrual and gynaecological history — regular cycles, LMP 4 days ago (still bleeding), no dysmenorrhoea history, no vaginal discharge except menstrual blood, no dyspareunia, not sexually active. Uses tampons only during menses.
Past medical history — no chronic illness, no drug allergies, no recent hospitalisations, no recent antibiotic use, fully immunised (childhood plus HPV plus COVID). Non-smoker, occasional social alcohol, no illicit drug use. Vegetarian diet.
Family history — no autoimmune disease, no vasculitis, no consanguinity.
On examination — appears critically ill, drowsy but rousable, cannot maintain eye contact for long. Temperature 40.0 degrees Celsius, pulse 130/min regular, RR 26/min, BP 82/48 (postural drop not testable — she cannot stand), SpO2 94 percent on room air, capillary refill 4 seconds, warm peripheries initially but cooling in the last 2 hours per emergency triage note.
Skin — diffuse macular erythroderma sparing no area — a bright red "sunburn-like" rash on trunk, face, arms, thighs, palms, and soles. The rash blanches on pressure. Palms and soles are erythematous and mildly swollen. No petechiae, no purpura, no target lesions, no vesicles, no bullae, Nikolsky sign negative. No local skin infection or abscess visible on inspection.
Mucous membranes — bilateral bulbar conjunctival hyperaemia without discharge (non-purulent). Strawberry tongue with prominent fungiform papillae over a bright red background. Diffuse pharyngeal erythema without tonsillar exudate. Cracked erythematous lips.
Cervical and other lymph nodes — mild bilateral cervical lymphadenopathy, none over 1 cm.
Cardiovascular — sinus tachycardia at 130, weak volume peripheral pulses, no murmur, no S3. JVP not elevated.
Respiratory — clear breath sounds bilaterally, no crackles, no wheeze.
Abdomen — soft, mild diffuse tenderness, no rebound, no organomegaly, bowel sounds increased. Suprapubic tenderness present.
Pelvic examination (performed after informed consent, with a female chaperone) — super-absorbent tampon in situ, saturated but not overtly foul-smelling; cervix mildly erythematous; no cervical motion tenderness; scanty menstrual bleeding; no adnexal tenderness. The tampon is removed and sent for culture; the vagina is irrigated with warm saline. The patient is not sexually active and cervical excitation is absent — pelvic inflammatory disease is unlikely.
Extremities — non-pitting mild puffiness of hands and feet, palm and sole erythema, tender to palpation, mild myalgia elicited on light pressure over quadriceps and calves.
CNS — drowsy but rousable, GCS 13 (E3 V4 M6), oriented to person but disoriented to time and place, no meningism, no focal deficits, reflexes normal.
The emergency medicine registrar recognises the pattern and initiates simultaneous resuscitation, urgent labs, tampon removal, and empiric antibiotics with a working diagnosis of menstrual staphylococcal toxic shock syndrome — CDC-criteria positive.
Initial assessment and the time-critical principles
Three principles govern the first hour.
Principle 1 — Remove the source before or immediately after starting antibiotics. In menstrual TSS the tampon is the reservoir of the toxin-producing S. aureus and TSST-1; leaving it in place while giving fluids and antibiotics doubles the mortality. In non-menstrual TSS the source is a wound, abscess, packing, or necrotising soft-tissue infection — needs urgent surgical exploration and debridement.
Principle 2 — Add a protein-synthesis inhibitor (clindamycin or linezolid) to the beta-lactam or vancomycin. Beta-lactams alone can lyse organisms and paradoxically increase circulating toxin. Clindamycin suppresses toxin production even before the organism is killed (the Eagle effect adjunct); this is standard of care in TSS.
Principle 3 — Do not delay antibiotics for imaging or cultures. The Surviving Sepsis Campaign first-hour bundle requires antibiotic administration within 60 minutes of suspected septic shock. Cultures are drawn concurrently, not before.
ABCDE
- A — Airway: patent, protecting airway with GCS 13; anticipate intubation if GCS deteriorates further or if aspiration risk rises with vomiting.
- B — Breathing: RR 26, SpO2 94 percent on room air. High-flow oxygen 15 L via non-rebreather; monitor for ARDS (rising oxygen requirement, bilateral infiltrates).
- C — Circulation: BP 82/48, pulse 130. Two 16G IV lines. Rapid 30 mL/kg (2 L) crystalloid bolus over 30 minutes; reassess perfusion. Central line and arterial line as soon as norepinephrine is started.
- D — Disability: GCS 13, oriented only to person; check glucose, temperature.
- E — Exposure: as above; remove tampon, examine skin fully, check for wound or abscess.
Tier 1 investigations (bedside, within 30 min)
- Bedside glucose 106 mg/dL (normal).
- Point-of-care lactate 5.2 mmol/L (markedly elevated — hypoperfusion, severe illness marker).
- VBG or ABG — pH 7.28, pCO2 30, HCO3 14, base excess -10, pO2 68 (room air), anion gap 22 — high-anion-gap metabolic acidosis (lactic) with respiratory compensation.
- ECG — sinus tachycardia at 130, no ischaemic changes, no arrhythmia.
- Bedside abdominal and pelvic ultrasound — no free fluid, no adnexal mass, empty bladder, no hydronephrosis.
- Chest X-ray — clear lung fields at presentation (no ARDS yet, but monitor).
Tier 2 laboratory investigations
- CBC — Hb 12.4 g/dL, WBC 22,000/microL with left shift (85 percent neutrophils, 15 percent bands), platelets 78,000/microL (thrombocytopenia — supports).
- CRP 24 mg/dL (markedly elevated).
- Procalcitonin 18 ng/mL (markedly elevated — bacterial infection).
- Renal panel — creatinine 2.1 mg/dL (baseline normal for age; over twice normal), urea 88 mg/dL, eGFR 32 mL/min, Na 132, K 4.8, Cl 96, HCO3 14.
- Liver panel — AST 240, ALT 300, ALP 180, GGT 96, total bilirubin 3.5 mg/dL, direct bilirubin 2.1 (over twice normal — supports).
- CPK 800 U/L (over twice normal — supports; monitor for rhabdomyolysis — check urine myoglobin).
- INR 1.8, aPTT 42 s, fibrinogen 480 mg/dL, D-dimer 4.2 mcg/mL (mild coagulopathy — DIC screen).
- Urine routine — mild proteinuria, 15 WBC per HPF without organisms (sterile pyuria — supports), no red cell casts, dipstick positive for blood (myoglobinuria).
- Blood cultures times two (aerobic and anaerobic) — sent (5-15 percent positive for S. aureus in menstrual TSS; higher in streptococcal TSS).
- Vaginal swab and tampon culture — sent (S. aureus grown in menstrual TSS in over 90 percent).
- Throat swab culture — sent (rules out group A Streptococcus).
- Serology — leptospirosis IgM, dengue NS1 and IgM, chikungunya, scrub typhus, malaria smear plus rapid diagnostic test, HIV, hepatitis B and C — sent to rule out tropical differentials in India.
- Measles IgM — sent (negative expected — fully immunised).
- Beta-hCG — negative (not pregnant — important before imaging and drugs).
Interpretation: meets CDC classic staphylococcal toxic shock syndrome criteria — fever at or above 38.9 (40.0), diffuse macular erythroderma, hypotension (82/48), multi-organ involvement in 6 of 7 systems (GI vomiting-diarrhoea, muscular myalgia and CPK over twice normal, mucous membranes conjunctival and pharyngeal hyperaemia and strawberry tongue, renal creatinine over twice normal plus sterile pyuria, hepatic bilirubin and transaminases over twice normal, haematologic platelets under 100,000, CNS disorientation), plus desquamation of palms and soles is expected at 1-2 weeks. Menstrual TSS with tampon source. Ready for empiric antibiotics plus resuscitation plus source removal.
The diagnostic algorithm — CDC criteria and the TSS differential
NEET PG tests the CDC criteria in detail.
CDC 1997 (updated 2011) criteria for staphylococcal TSS
All 5 clinical criteria plus 2 laboratory criteria required:
- Fever at or above 38.9 degrees Celsius
- Rash — diffuse macular erythroderma (sunburn-like)
- Desquamation of palms and soles 1-2 weeks after onset
- Hypotension — systolic BP under 90 mmHg in adults, orthostatic drop over 15 mmHg, or under 5th centile in children
- Multisystem involvement — 3 or more of:
- GI — vomiting or diarrhoea at onset
- Muscular — severe myalgia or CPK over twice normal
- Mucous membrane — vaginal, oropharyngeal, or conjunctival hyperaemia
- Renal — creatinine over twice normal OR sterile pyuria (over 5 WBC per HPF)
- Hepatic — bilirubin or transaminases over twice normal
- Haematologic — platelets under 100,000/microL
- CNS — disorientation or altered consciousness without focal neurology (in absence of fever and hypotension)
Laboratory criteria:
- Negative blood, throat, or CSF cultures for other organisms (blood culture may be positive for S. aureus)
- Negative serology for Rocky Mountain spotted fever, leptospirosis, and measles
Case classification:
- Confirmed — all 5 clinical plus laboratory criteria met
- Probable — 4 of 5 clinical criteria plus laboratory criteria
CDC criteria for streptococcal TSS (STSS due to Group A Streptococcus)
Isolation of group A Streptococcus PLUS hypotension PLUS 2 or more of:
- Renal impairment — creatinine over 2 mg/dL (or over twice baseline)
- Coagulopathy — platelets under 100,000 OR DIC
- Hepatic involvement — ALT, AST, or bilirubin over twice normal
- ARDS
- Generalised erythematous macular rash (may desquamate)
- Soft-tissue necrosis — necrotising fasciitis, myositis, gangrene
Confirmed — GAS from a normally sterile site (blood, CSF, pleural fluid, tissue biopsy).
Probable — GAS from a non-sterile site (throat, wound swab).
Superantigen pathogenesis (the mechanism NEET PG asks)
Superantigens (TSST-1, SEA-SEE, SpeA-C) bypass normal antigen processing. They cross-link the Vbeta chain of the T-cell receptor directly to the outer surface of MHC class II on antigen-presenting cells. This activates 20-30 percent of the T-cell pool simultaneously (vs 0.001 percent for conventional antigens). Massive cytokine release — IL-2, IFN-gamma, TNF-alpha, IL-1beta, IL-6 — drives distributive shock, capillary leak, coagulopathy, multi-organ dysfunction, and the rash.
Differential diagnosis
| Diagnosis | Distinguishing features | Confirmation |
|---|
| Septic shock (gram-negative or gram-positive bacteraemia) | Focus of infection (pneumonia, UTI, intra-abdominal), positive blood cultures, no diffuse rash | Blood cultures, source imaging |
| Meningococcaemia | Petechial and purpuric rash, neck stiffness, meningeal signs, CSF changes | CSF, blood culture, PCR |
| Leptospirosis | Water exposure, jaundice, conjunctival suffusion, hepatorenal failure, myalgia | MAT, IgM serology |
| Scrub typhus | Rural exposure, eschar, fever, rash, ARDS | Weil-Felix, IgM ELISA, doxycycline response |
| Dengue haemorrhagic fever | Petechiae, low platelets, plasma leak, positive NS1 or IgM | NS1, IgM |
| Malaria (severe P. falciparum) | Endemic exposure, haemolytic anaemia, cerebral malaria | Peripheral smear, RDT |
| Kawasaki disease | Children usually, meets AHA criteria, subacute course, no shock at onset | Clinical criteria |
| Scarlet fever | Sandpaper rash, tonsillar exudate, throat culture positive for GAS | Throat culture, ASO |
| SJS / TEN | Drug trigger, mucositis with target lesions, epidermal detachment (Nikolsky positive) | Drug history, skin biopsy |
| Erythema multiforme major | Target lesions, drug or infection trigger | Skin biopsy |
| DRESS syndrome | Drug exposure 2-6 weeks earlier, eosinophilia, atypical lymphocytes | Drug history, RegiSCAR score |
| Staphylococcal scalded skin syndrome (SSSS) | Children usually, Nikolsky positive, superficial peel | Clinical, skin biopsy |
| Anaphylaxis | Rapid onset after exposure, wheeze, urticaria, angio-oedema | History, tryptase |
Menstrual vs non-menstrual TSS
| Feature | Menstrual TSS | Non-menstrual TSS |
|---|
| Source | Tampon, menstrual cup, contraceptive sponge | Post-surgical wound, nasal packing, burn, cesarean, soft-tissue infection, post-partum |
| Toxin | TSST-1 (over 90 percent) | TSST-1 (60 percent), SEs (40 percent) |
| Age | Young women 15-30 | Any age, both sexes |
| Positive blood culture | 5 percent (source is mucosal, not systemic) | 10-20 percent |
| Mortality | 5-10 percent | 5-15 percent |
| Recurrence | 30 percent if tampon use continues | Rare |
| Preventable | Yes — tampon hygiene | Yes — wound care, early debridement |
Note: streptococcal TSS is usually non-menstrual, associated with skin/soft-tissue infection, has 30-70 percent mortality (much higher), and 60 percent blood culture positivity.
Why our patient is classic menstrual staphylococcal TSS
Ten features confirm it: (1) fever 40 degrees Celsius, (2) diffuse sunburn-like erythroderma, (3) hypotension 82/48, (4) menstrual tampon in situ (source), (5) GI — vomiting and diarrhoea, (6) muscular — severe myalgia and CPK 800, (7) mucous membrane — conjunctival hyperaemia, strawberry tongue, cracked lips, (8) renal — creatinine 2.1 and sterile pyuria, (9) hepatic — bilirubin 3.5 and ALT 300, (10) haematologic — platelets 78,000. Also CNS — GCS 13 disorientation. Lactate 5.2 supports severity. Desquamation of palms and soles expected at 1-2 weeks.
Diagnosis
Menstrual staphylococcal toxic shock syndrome (CDC-criteria confirmed) in a 22-year-old woman on day 4 of menses using a super-absorbent tampon, with fever 40 degrees Celsius, diffuse macular erythroderma, hypotension (BP 82/48), and multi-organ dysfunction across 7 systems (GI, muscular, mucous membrane, renal, hepatic, haematologic, CNS) — for immediate tampon removal and vaginal irrigation, sepsis-bundle resuscitation, empiric vancomycin plus clindamycin plus piperacillin-tazobactam, norepinephrine to MAP over 65, and consideration of IVIG for refractory shock or streptococcal source confirmation.
Management — first hour, first 24 hours, first week, discharge, long-term
First hour — Surviving Sepsis first-hour bundle plus TSS-specific additions
- Source control (TSS-specific, immediate) — remove the tampon (already done at pelvic exam), irrigate the vagina with warm saline; if any surgical wound, packing, or soft-tissue focus present, arrange urgent surgical exploration and debridement.
- Measure lactate (already 5.2 mmol/L — severe).
- Blood cultures — obtain 2 sets (aerobic and anaerobic) BEFORE antibiotics (but do not delay antibiotics if unable to obtain immediately).
- Empiric broad-spectrum antibiotics within 60 minutes — vancomycin 25-30 mg/kg IV loading dose (about 2 g in a 60 kg adult) then 15-20 mg/kg every 8-12 hours (target trough 15-20 mcg/mL) PLUS clindamycin 900 mg IV every 8 hours (protein-synthesis inhibitor, Eagle-effect adjunct to suppress toxin production — MANDATORY) PLUS piperacillin-tazobactam 4.5 g IV every 6 hours OR meropenem 1 g IV every 8 hours (broad gram-negative and anaerobic cover for source uncertainty and possible synergy for streptococcal cover). Continue for 10-14 days depending on source control adequacy; de-escalate after culture results.
- Crystalloid bolus — 30 mL/kg (2 L in a 60 kg adult) of balanced crystalloid (Ringer's lactate or Plasmalyte) over 30 minutes; reassess perfusion, MAP, lactate, capillary refill after each bolus.
- Vasopressor — if MAP remains under 65 after fluid resuscitation, start norepinephrine 0.05-0.5 mcg/kg/min titrated to MAP over 65. Insert central venous catheter (subclavian or internal jugular preferred over femoral for infection risk).
- Add vasopressin 0.03 U/min as second agent if norepinephrine dose exceeds 0.25 mcg/kg/min.
- Hydrocortisone 200 mg/day IV (as 50 mg every 6 hours or continuous infusion) for refractory shock requiring escalating vasopressors (ADRENAL, APROCCHSS).
- Arterial line for beat-to-beat BP; urinary catheter for urine output measurement (target over 0.5 mL/kg/hr).
- Consider IVIG 2 g/kg as single infusion OR 1 g/kg day 1 plus 0.5 g/kg days 2-3 — strongly recommended for streptococcal TSS and for severe or refractory staphylococcal TSS with multi-organ dysfunction. Our patient's severity (lactate 5.2, GCS 13, 7-system involvement) is a strong indication.
- Correct coagulopathy — FFP for INR over 1.5 with active bleeding or planned procedure; platelet transfusion if platelets under 20,000 or under 50,000 with active bleeding.
- Withhold NSAIDs, hold ACEi if hypotensive, correct electrolytes (K, Mg, Ca, phosphate).
- VTE prophylaxis — after coagulopathy addressed, LMWH prophylactic dose (enoxaparin 40 mg SC OD or 30 mg BD, adjust for renal function).
- Stress-ulcer prophylaxis — pantoprazole 40 mg IV OD.
First 24 hours — organ support and reassessment
- Continue fluid resuscitation guided by dynamic markers — pulse pressure variation, passive leg raise, bedside echocardiography (not static CVP alone)
- Continue norepinephrine, wean as MAP recovers and lactate clears
- Reassess for ARDS — daily chest X-ray, PaO2:FiO2 ratio; initiate lung-protective ventilation (Vt 6 mL/kg predicted body weight, plateau pressure under 30, PEEP titrated) if intubated
- Reassess renal function — trend creatinine and urine output; initiate CRRT (continuous renal replacement therapy) or intermittent haemodialysis for oliguric AKI, refractory hyperkalaemia, refractory acidosis, uraemic complications, or fluid overload
- Reassess coagulation — DIC panel (platelets, INR, aPTT, fibrinogen, D-dimer, ISTH DIC score); FFP, cryoprecipitate, platelet transfusion as needed
- Reassess CNS — GCS trend, exclude meningoencephalitis (lumbar puncture if suspicion) and ICU delirium
- Cultures and de-escalation — narrow antibiotics based on organism and sensitivity; if MRSA confirmed, continue vancomycin; if MSSA, switch to cefazolin or nafcillin/oxacillin; continue clindamycin for at least 5 days for anti-toxin effect regardless
- Nutrition — early enteral nutrition within 24-48 hours if bowel function permits; parenteral only if enteral fails
- Glycaemic control — target 140-180 mg/dL (avoid hypoglycaemia)
- Sedation-analgesia protocol with daily awakening trials in intubated patients
First week — recovery, de-escalation, and complication surveillance
- Antibiotic duration — 10-14 days total (longer if source control incomplete, deep-seated infection, or endocarditis)
- Vasopressor weaning — reduce norepinephrine as MAP and lactate stabilise; discontinue hydrocortisone (tapering not required for short courses under 7 days)
- Extubation when meeting standard criteria (PaO2:FiO2 over 200, PEEP under 8, minimal sedation, spontaneous breathing trial passed)
- AKI recovery — most cases recover; some require ongoing dialysis (5-10 percent)
- Coagulopathy resolution — DIC typically resolves in 3-7 days with source control and antibiotics
- Skin manifestations — the sunburn rash fades in 4-7 days; desquamation of palms and soles at 10-21 days is expected and is a diagnostic hallmark; nail changes and hair loss may follow
- Physiotherapy and rehabilitation — early mobilisation prevents ICU-acquired weakness
- Nutritional and psychosocial support — TSS survivors often have prolonged fatigue, cognitive slowing, and post-ICU syndrome
Discharge planning
- Confirmed diagnosis and root-cause counselling — explain tampon-associated TSS, the mechanism, and the recurrence risk
- Absolute avoidance of tampons and menstrual cups for life after menstrual TSS (30 percent recurrence risk) — switch to sanitary pads only
- Staphylococcus decolonisation — intranasal mupirocin twice daily for 5 days plus chlorhexidine body wash for 5 days; repeat every 3-6 months for the first year; consider swab of nares and axillae to confirm eradication
- Medication reconciliation and follow-up — infectious disease clinic at 2 weeks, primary care at 1 week, gynaecology at 4-6 weeks
- Vaccinations — update per age-appropriate schedule; no live-vaccine restrictions from TSS itself
- Awareness card and family education — recognise early warning signs (fever, rash, vomiting/diarrhoea on menses); seek immediate care
- Return-to-work / study — often 4-8 weeks depending on severity; graded return-to-work programme
Long-term
- Post-ICU syndrome surveillance — physical, cognitive, mental health domains; refer to post-ICU clinic if available
- Chronic renal impairment — small proportion have persistent CKD; annual creatinine and urine albumin-creatinine ratio
- Cardiovascular risk — severe sepsis survivors have elevated 5-year cardiovascular event risk; standard prevention
Complications
Acute (hospitalisation)
- Cardiogenic and distributive shock — leading cause of early death
- Acute kidney injury — over 50 percent of severe cases require CRRT
- ARDS — 25-30 percent of severe cases; long ICU stay
- DIC and bleeding — 20-30 percent
- Rhabdomyolysis and myoglobinuria — supportive; risk of AKI
- Multiorgan failure — driver of mortality
- Nosocomial infections — VAP, CLABSI, CAUTI
Subacute (weeks-months)
- Desquamation of palms and soles at 10-21 days — classic
- Hair loss and nail changes
- Prolonged fatigue, cognitive impairment
- Recurrence in 30 percent of menstrual TSS survivors if tampons continued
Long-term
- Post-ICU syndrome — physical weakness, cognitive impairment, PTSD
- Chronic kidney disease — in about 5 percent
- Reduced fertility — a small proportion have oligomenorrhoea or amenorrhoea after severe menstrual TSS
- Neuropsychiatric sequelae — memory impairment, depression, anxiety
India-specific considerations
- Rare but rising — tampon use in India is still low (roughly 15-20 percent of urban menstruating women vs over 70 percent in the US and UK), so menstrual TSS is uncommon but is being reported more frequently in urban hospital case series as tampon and menstrual-cup adoption rises among young college and working women
- Under-diagnosed non-menstrual TSS — post-cesarean, post-septoplasty (nasal packing), post-mastectomy, post-burn, and community-acquired MRSA soft-tissue infections are under-recognised in Indian ICUs; a low threshold for TSS in any fever-plus-rash-plus-hypotension-plus-multiorgan patient is essential
- Community-acquired MRSA (CA-MRSA) rising — particularly USA300 clone; contributes to the changing epidemiology of soft-tissue infections and non-menstrual TSS in urban India
- Tropical differentials must be excluded — dengue, malaria, scrub typhus, leptospirosis, chikungunya can all present with fever plus rash plus shock plus multi-organ dysfunction; empiric doxycycline should be considered while awaiting serology in appropriate exposures, given the low toxicity and clear benefit for rickettsial disease
- IVIG cost and access — 2 g/kg dose is Rs 1.5-3 lakh; PMJAY covers select indications; social work engagement early is critical
- Clindamycin availability — widely available in Indian hospital formularies; cost is low; do not omit for cost reasons in TSS
- Menstrual hygiene education — under-provided; SHE Pad Bank, Menstrual Health Alliance India, and similar organisations are working to expand safe menstrual product access; NEET PG-qualified doctors should reinforce tampon rotation and safety in every consultation with a young woman using tampons
- Post-surgical wound care — Indian tertiary hospitals need to strengthen surgical-wound TSS surveillance; ID and infection-control liaison
How NEET PG tests toxic shock syndrome
Nine recurring patterns.
Pattern 1 — The CDC criteria question: Vignette gives fever, sunburn rash, hypotension, multi-organ dysfunction in a young woman on menses; asks the diagnosis. Menstrual staphylococcal toxic shock syndrome.
Pattern 2 — The superantigen mechanism question: How does TSST-1 cause TSS? Cross-links Vbeta chain of the T-cell receptor to MHC class II bypassing antigen processing, activating 20-30 percent of the T-cell pool and causing a cytokine storm (IL-2, IFN-gamma, TNF-alpha, IL-1, IL-6).
Pattern 3 — The antibiotic combination question: Why is clindamycin added to vancomycin in TSS? Clindamycin is a protein-synthesis inhibitor that suppresses toxin production even before organism killing (Eagle-effect adjunct).
Pattern 4 — The source control question: First step in menstrual TSS presenting to ED? Remove the tampon immediately, then irrigate the vagina, then antibiotics plus fluids.
Pattern 5 — The IVIG question: Which type of TSS is IVIG most strongly recommended for? Streptococcal TSS (and severe or refractory staphylococcal TSS). Dose 2 g/kg single or 1 g/kg day 1 plus 0.5 g/kg days 2-3.
Pattern 6 — The staphylococcal vs streptococcal TSS question: Mortality contrast? Staph TSS 5-15 percent, Strep TSS 30-70 percent. Blood culture positivity — Staph 5-15 percent, Strep 60 percent. Streptococcal TSS almost always has a soft-tissue focus (necrotising fasciitis, myositis, cellulitis).
Pattern 7 — The differential question: Fever plus rash plus shock in India — what to rule out first? Dengue, meningococcaemia, leptospirosis, scrub typhus, malaria alongside TSS; empiric doxycycline for rickettsial cover while awaiting serology.
Pattern 8 — The desquamation question: When does desquamation appear in TSS? 10-21 days after onset, on palms and soles; classic diagnostic hallmark.
Pattern 9 — The recurrence and prevention question: Recurrence rate of menstrual TSS if tampon use continues? 30 percent. Prevention — tampon rotation every 4-8 hours, lowest absorbency, alternate with pads, no tampons after recurrent TSS, Staphylococcus decolonisation with mupirocin plus chlorhexidine.
High-yield one-liners:
- CDC criteria — fever plus rash plus hypotension plus desquamation plus 3-of-7 organ systems
- TSST-1 causes over 90 percent of menstrual staphylococcal TSS
- Superantigens cross-link Vbeta TCR to MHC II bypassing antigen processing
- Massive cytokine release drives distributive shock, capillary leak, MOF, and rash
- Clindamycin (or linezolid) is mandatory add-on to beta-lactam or vancomycin — Eagle-effect toxin suppression
- Empiric antibiotics — vancomycin plus clindamycin plus piperacillin-tazobactam or meropenem
- Source control is the single highest-priority intervention — remove tampon, drain wound, debride necrotising fasciitis
- 30 mL/kg crystalloid, norepinephrine first-line, vasopressin second, hydrocortisone for refractory shock
- IVIG 2 g/kg for streptococcal TSS and severe or refractory staphylococcal TSS
- Streptococcal TSS mortality 30-70 percent, blood culture positive in 60 percent
- Staphylococcal TSS mortality 5-15 percent, blood culture positive in only 5-15 percent
- Desquamation of palms and soles at 10-21 days is a diagnostic hallmark
- Recurrence 30 percent for menstrual TSS if tampons continued — lifelong sanitary pads only
- Decolonisation — intranasal mupirocin plus chlorhexidine body wash
- Always rule out tropical fevers (dengue, malaria, scrub typhus, leptospirosis) in India
Frequently Asked Questions
What are the CDC diagnostic criteria for staphylococcal toxic shock syndrome and how do they differ from streptococcal TSS?
The CDC 1997 criteria (updated 2011) for staphylococcal toxic shock syndrome (STSS due to Staphylococcus aureus) require all five clinical features and both laboratory criteria. Clinical criteria are (1) fever at or above 38.9 degrees Celsius, (2) diffuse macular erythroderma (a sunburn-like rash), (3) desquamation of palms and soles 1-2 weeks after onset of illness, (4) hypotension defined as systolic BP under 90 mmHg in adults or under 5th centile for age in children, and (5) multisystem involvement — 3 or more organ systems from gastrointestinal (vomiting or diarrhoea at onset), muscular (severe myalgia or CPK over twice normal), mucous membrane (vaginal, oropharyngeal, or conjunctival hyperaemia), renal (creatinine over twice normal or over 5 white cells per HPF without UTI), hepatic (bilirubin or transaminases over twice normal), haematologic (platelets under 100,000), and central nervous system (disorientation or altered consciousness without focal neurology when fever and hypotension are absent). Laboratory criteria require negative results for blood, throat, or CSF cultures for other pathogens (blood culture may be positive for S. aureus) and negative serologies for Rocky Mountain spotted fever, leptospirosis, and measles. Streptococcal TSS (due to group A Streptococcus) has a separate CDC case definition — isolation of group A Streptococcus PLUS hypotension PLUS 2 or more of renal, hepatic, haematologic, ARDS, generalised erythematous macular rash (may desquamate), and soft-tissue necrosis (necrotising fasciitis, myositis, gangrene). Streptococcal TSS is more often associated with a soft-tissue infection, has positive blood cultures in 60 percent (compared with 5-15 percent for staphylococcal TSS), and carries a much higher mortality (30-70 percent vs 5-15 percent). NEET PG tests both case definitions and the mortality contrast.
How do superantigens cause toxic shock syndrome and why does that pathophysiology matter for treatment?
Superantigens are bacterial exotoxins — TSST-1 (toxic shock syndrome toxin-1, produced by S. aureus and responsible for over 90 percent of menstrual staphylococcal TSS), staphylococcal enterotoxins (SEA-SEE, notably SEB), and streptococcal pyrogenic exotoxins (SpeA, SpeB, SpeC in group A Streptococcus) — that bypass the normal MHC class II antigen-processing pathway. Instead of being processed by antigen-presenting cells and presented as short peptides in the antigen-binding groove of MHC II, superantigens cross-link the Vbeta chain of the T-cell receptor directly to the outer surface of MHC II, activating up to 20-30 percent of the T-cell population simultaneously (vs 0.001-0.0001 percent for conventional antigens). This triggers a massive cytokine storm — IL-2, IFN-gamma, TNF-alpha, IL-1beta, IL-6 — driving distributive shock, capillary leak, coagulopathy, multi-organ failure, and the rash and mucous membrane changes characteristic of TSS. Two therapeutic implications flow from this pathophysiology. First, antibiotic choice must include a protein-synthesis inhibitor to switch off toxin production — clindamycin (or linezolid) is added to a beta-lactam or vancomycin because beta-lactams alone can paradoxically increase toxin release from lysed organisms (the Eagle effect); the clindamycin add-on is standard of care in TSS. Second, intravenous immunoglobulin (IVIG) contains pooled donor antibodies that neutralise circulating superantigens; IVIG at 2 g/kg single dose (or 1 g/kg day 1 then 0.5 g/kg days 2-3) is strongly recommended for streptococcal TSS and for severe or refractory staphylococcal TSS. NEET PG tests both the superantigen mechanism and the clindamycin plus IVIG add-on.
What is the immediate resuscitation and source-control strategy for a patient in toxic shock?
The immediate management of TSS follows the standard sepsis and septic-shock bundle plus disease-specific additions. In the first hour, do airway, breathing, circulation, secure two large-bore IV lines and an arterial line, obtain lactate, blood cultures times two, and a full septic screen; start high-flow oxygen; give the first-hour bundle of a broad-spectrum antibiotic within 60 minutes and 30 mL/kg crystalloid bolus (2-3 L in a 60-70 kg adult); reassess perfusion. If MAP remains under 65 mmHg after fluid resuscitation, start intravenous norepinephrine as first-line vasopressor (target MAP over 65); add vasopressin 0.03 U/min as second agent; add hydrocortisone 200 mg/day IV in divided doses or infusion for refractory shock (SEP-1 bundle, ADRENAL and APROCCHSS trials). Insert a central venous catheter, urinary catheter, and consider invasive haemodynamic monitoring or bedside echocardiography (cardiac output-guided resuscitation). Simultaneously, remove the source — the most critical intervention in TSS. In menstrual TSS this means removing the tampon, menstrual cup, or contraceptive sponge and irrigating the vagina. In surgical TSS this means opening and draining the wound and debriding necrotic tissue in the operating theatre. In soft-tissue infection with streptococcal TSS this means an urgent surgical exploration to exclude and manage necrotising fasciitis — the LRINEC score is a triage tool but should never delay surgical exploration when clinical suspicion is high. Antibiotic choice is empiric broad-spectrum covering Staphylococcus (including MRSA), Streptococcus, and gram-negative organisms — vancomycin 25-30 mg/kg loading then 15-20 mg/kg every 8-12 hours (target trough 15-20 mcg/mL) PLUS clindamycin 900 mg IV every 8 hours (protein-synthesis inhibitor to suppress toxin production, the Eagle-effect adjunct) PLUS piperacillin-tazobactam 4.5 g every 6 hours or meropenem 1 g every 8 hours for broad gram-negative and anaerobic cover. De-escalate after culture data. Treat for 10-14 days depending on source control adequacy. NEET PG tests the fluid volume, the norepinephrine-first choice, the clindamycin add-on, and the source-control priority.
What is the role of intravenous immunoglobulin (IVIG) in toxic shock syndrome and when should it be used?
Intravenous immunoglobulin (IVIG) is a pooled preparation of donor antibodies that neutralises circulating superantigens and is recommended primarily for streptococcal toxic shock syndrome (STSS due to group A Streptococcus) and for severe, refractory, or high-mortality staphylococcal TSS. The evidence base is observational and one small RCT (Darenberg et al) rather than definitive high-quality randomised data — because of the low incidence of TSS, adequately powered RCTs have not been performed and are unlikely to be. Nevertheless, retrospective and observational series consistently show a survival benefit, particularly in streptococcal TSS with necrotising fasciitis or refractory shock. The recommended dose is either 2 g/kg as a single infusion OR a divided regimen of 1 g/kg on day 1 followed by 0.5 g/kg on days 2 and 3. IVIG is given as adjunct therapy alongside vancomycin plus clindamycin plus a broad-spectrum beta-lactam and source control — never as monotherapy. Monitoring during infusion is standard for IVIG — anaphylaxis, aseptic meningitis, thromboembolic events, acute kidney injury (particularly with sucrose-containing preparations, largely withdrawn), and volume overload (especially in patients with heart failure or renal impairment). IVIG is expensive (Rs 1.5-3 lakh for a 2 g/kg dose in a 60-70 kg adult in India) and PMJAY (Ayushman Bharat) coverage varies by indication; social work involvement early is important. Contraindications are IgA deficiency (risk of anaphylaxis to IVIG containing IgA) and severe volume overload. NEET PG tests the streptococcal-first indication, the 2 g/kg dose, and the adjunctive nature of IVIG.
How is toxic shock syndrome prevented and what is the rate of recurrence?
Primary prevention of menstrual toxic shock syndrome focuses on safe menstrual hygiene practices — use the lowest absorbency tampon needed for the flow, alternate tampons with sanitary pads (especially overnight), change tampons every 4-8 hours (never leave for more than 8 hours), avoid tampons overnight when practical, wash hands before and after insertion and removal, and consider menstrual cups (silicone cups have been associated with TSS as well, so the same 4-8 hour rotation rule applies). Awareness of early warning signs is critical — sudden high fever, sunburn-like rash, vomiting or diarrhoea, headache, sore throat, muscle aches, or dizziness during a menstrual period on tampon use warrants immediate tampon removal and emergency assessment. Non-menstrual TSS prevention focuses on early recognition and management of post-surgical wound infections (particularly nasal packing after septoplasty, post-cesarean, post-mastectomy), soft-tissue infections (early debridement of necrotising fasciitis, cellulitis, and burns), and post-partum management. Recurrent menstrual TSS is a major risk — approximately 30 percent of survivors of the first episode will have recurrence if they continue tampon use; recurrence is often more severe. Management of recurrence risk includes lifelong avoidance of tampons and menstrual cups, use of sanitary pads only, and Staphylococcus decolonisation with intranasal mupirocin twice daily for 5 days plus chlorhexidine body wash for 5 days, repeated as needed. Some clinicians recommend anti-toxin antibody testing (adult neutralising antibody to TSST-1 is protective and only 30-40 percent of first-episode TSS survivors have seroconverted). NEET PG tests both the primary prevention advice (tampon rotation, absorbency) and the 30 percent recurrence risk requiring tampon-avoidance.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team
Reviewed by: Pending SME Review
Last reviewed: August 2026
